{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:12:39Z","timestamp":1778573559024,"version":"3.51.4"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>We present the case of a 33-year-old female with a 4.3 \u00d7 3.2\u00a0cm high-density mass in the apical segment of the right upper lobe, detected on non-contrast chest CT, which showed suspected invasion of the chest wall and other tissues. CT-guided lung biopsy confirmed lung adenocarcinoma, and genetic testing revealed an EGFR exon 19 deletion. The patient received neoadjuvant therapy with oral Osimertinib combined with chemotherapy. After 4\u00a0months of treatment, she underwent thoracoscopic right upper lobectomy, mediastinal lymph node dissection, and pleural adhesion lysis. Postoperative management included anti-infection therapy, expectorants, nebulization, and analgesia. The patient recovered well and was discharged on postoperative day five, with good general condition at follow-up. This case illustrates that neoadjuvant targeted therapy combined with chemotherapy can convert locally unresectable lung cancer to a resectable status and improve operative feasibility, thus offering valuable insights for clinical management.<\/jats:p>","DOI":"10.3389\/fphar.2026.1695807","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:38:27Z","timestamp":1778571507000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The combination of osimertinib and chemotherapy successfully enabled surgical resection of locally advanced lung adenocarcinoma: a Case Report"],"prefix":"10.3389","volume":"17","author":[{"given":"Cheng-Yi","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun-Xian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Yu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11782","DOI":"10.1038\/s41598-024-60414-x","article-title":"Down-regulation of KLRB1 is associated with increased cell growth, metastasis, poor prognosis, as well as a dysfunctional immune microenvironment in LUAD","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"21654","DOI":"10.1038\/s41598-025-05259-8","article-title":"Caveolin-1 inhibits the proliferation and invasion of lung adenocarcinoma via EGFR degradation","volume":"15","author":"Dong","year":"2025","journal-title":"Sci. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e7208","DOI":"10.1002\/cam4.7208","article-title":"Prognostic implications of combining EGFR-TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19-Del or 21-L858R mutations: a real-world study","volume":"13","author":"Liang","year":"2024","journal-title":"Cancer Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"108456","DOI":"10.1016\/j.lungcan.2025.108456","article-title":"Gefitinib for EGFR mutated lung adenocarcinoma during pregnancy: a case report with 5-Year Follow-Up","volume":"202","author":"Messekher","year":"2025","journal-title":"Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"108587","DOI":"10.1016\/j.lungcan.2025.108587","article-title":"Unusual relapse dynamics in EGFR-Mutated lung adenocarcinoma uncovered by genomic profiling: insights from a case report","volume":"204","author":"Roma","year":"2025","journal-title":"Lung Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.20344\/amp.22031","article-title":"Osimertinib: a game-changer in stage IV EGFR-driven lung cancer","volume":"38","author":"Silva","year":"2025","journal-title":"Acta Med. Port."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.2169\/internalmedicine.4427-24","article-title":"Alternating administration of osimertinib for leptomeningitis and docetaxel plus ramucirumab for lung adenocarcinoma resistant to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"64","author":"Tomizawa","year":"2025","journal-title":"Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1016\/j.cllc.2018.04.004","article-title":"ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection","volume":"19","author":"Wu","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e32025","DOI":"10.1016\/j.heliyon.2024.e32025","article-title":"Downregulation of DIP2B as a prognostic marker inhibited cancer proliferation and migration and was associated with immune infiltration in lung adenocarcinoma via CCND1 and MMP2","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2501780","DOI":"10.1080\/15384047.2025.2501780","article-title":"Silencing ZIC5 suppresses glycolysis and promotes disulfidptosis in lung adenocarcinoma cells","volume":"26","author":"Zeng","year":"2025","journal-title":"Cancer Biol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.21037\/jtd-23-161","article-title":"Expression of EGFR-Mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer","volume":"15","author":"Zhang","year":"2023","journal-title":"J. Thorac. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1695807\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:38:29Z","timestamp":1778571509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1695807\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":13,"alternative-id":["10.3389\/fphar.2026.1695807"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1695807","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"article-number":"1695807"}}